Kymera Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Kymera Therapeutics

25/02/2025 14:22

Kymera Therapeutics Inc KYMR.OQ KYMR.O is expected to show a fall in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

The Watertown Massachusetts-based  company is expected to report a 75.3% decrease in revenue to $11.82 million from $47.88 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Kymera Therapeutics Inc is for a loss of 77 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $57.00​, above​ its last closing price of $35.31. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.84
-0.84
-0.82
Beat
2.2
Jun. 30 2024
-0.66
-0.68
-0.58
Beat
15.1
Mar. 31 2024
-0.74
-0.73
-0.62
Beat
14.7​
Dec. 31 2023
-0.42
-0.40
-0.25
Beat
38.3
​​Sep. 30 2023
-0.73
-0.64
-0.90
Missed
-40.3
Jun. 30 2023
-0.76
-0.64
-0.67
Missed
-5.2​
Mar. 31 2023
-0.71
-0.68
-0.70
Missed
-3.3
Dec. 31 2022
-0.49
-0.63
-0.60
Beat
5.2

This summary was machine generated February 25 at 14:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)